United States· US:65862-862_389b20f0-64d5-46f6-bb3b-74feb1a9898b
Darifenacin
A darifenacin product containing darifenacin hydrobromide, registered in United States by Aurobindo Pharma Limited. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Darifenacin is registered in 15 of 19 countries.
Countries holding a registration under ATC G04BD10 (darifenacin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Darifenacin · ATC G04BD10
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of darifenacin costs, country by country.
Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Darifenacin · price per daily dose (7.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.84
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DARIFENACIN HYDROBROMIDE
- Manufacturer
- Aurobindo Pharma Limited
- Country
- United States (US)
- ATC code
- G04BD10
- ATC class
- Darifenacin
- Defined daily dose
- 7.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 8
- ndc1165862-862-05
- ndc1165862-862-30
- ndc1165862-862-90
- ndc1165862-862-99
- ndc116586286205500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-862-05)
- ndc11658628623030 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-862-30)
- ndc11658628629090 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-862-90)
- ndc1165862862991000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-862-99)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
246 interactions on record for darifenacin.
Graded by severity as the source publishes them — 13 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Darifenacin · interactions on record
246 records
- 13 severe
- 155 moderate
- 1 minor
- 49 info
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- EliglustatA16AX10severe
- Potassium chlorideB05XA01severe
28 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Darifenacin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEMSELEXpharmaand GmbH, Vienna
- United KingdomDarifenacin 15mg modified-release tabletsA A H Pharmaceuticals Ltd
- CanadaAPO-DARIFENACINAPOTEX INC
- PolandDarifenacin AristoAristo Pharma Sp. z o.o.
- SwitzerlandEmselex
- NetherlandsDarifenacine Aristo 15 mg tabletten met verlengde afgifteAristo Pharma GmbH
- NorwayEmselexpharmaand GmbH
- BelgiumEmselex 15 mgpharmaand
Authorised across Europe · EMA
The same active substance is authorised in 8 EEA countries. Names it is sold under:
- Germany · Darifenacin Aristo
- Spain · Darifenacina Aristo
- United Kingdom (Northern Ireland) · Darifenacin Aristo
- Iceland · Emselex
- Liechtenstein · Emselex
- Netherlands · Darifenacine Aristo
- Norway · Emselex
- Portugal · Darifenacina Aristo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da8d25e4-2021-4692-8ed6-307fd8fc6e03 GET /v1/drugs/da8d25e4-2021-4692-8ed6-307fd8fc6e03?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "15",
"substance": "DARIFENACIN HYDROBROMIDE",
"productndc": "65862-862",
"dosage_form": "TABLET, FILM COATED, EXTENDED RELEASE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA206743",
"marketing_category": "ANDA"
}See everything about darifenacin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.